[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640319":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":34,"responsibleParty":46,"collaborators":11,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":11,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":74,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Taipei Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"AI chatbot-enabled nurse-led program","EXPERIMENTAL",null,[13],"Other: AI chatbot-enabled nurse-led program.",{"label":15,"type":6,"description":16,"interventionNames":17},"Control group","Usual care based on standard outpatient follow-up, without access to the AI chatbot or nurse-led coordination",[18],"Other: Usual Care",[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"AI chatbot-enabled nurse-led program.","Participants in the intervention group will receive a six-month nurse-led, AI chatbot-enabled symptom monitoring and self-management program integrating weekly ePRO assessments. The intervention begins with a structured nurse-led intake session including CKM assessment, symptom review, goal setting, and training on chatbot use. Participants complete weekly PROMIS-29 v2.1 assessments via a smartphone-based chatbot, which provides automated, rule-based feedback, self-management guidance, and motivational prompts. A risk-stratification algorithm generates alerts when symptom deterioration is detected. Nurses review alerts daily and provide follow-up via messaging, teleconsultation, or referral depending on severity, with same-day escalation for high-risk symptoms.",[9],{"type":6,"name":25,"description":16,"armGroupLabels":26,"otherNames":11},"Usual Care",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Pei Shan Tsai, PhD in Nursing","CONTACT","+886 2 2736 1661","6300","ptsai@tmu.edu.tw",[35],{"facility":5,"status":11,"city":36,"state":37,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":11},"Taipei","No. 250號, Wuxing St, Xinyi District, Taipei City, 110","Taiwan","TW",{"type":41,"coordinates":42},"Point",[43,44],121.52639,25.05306,{"lat":44,"lon":43},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Pei-Shan, Tsai","Principal Investigator","100640319","ai-chatbot-enabled-epro-symptom-monitoring-and-self-management-for-early-cardiovascular-kidney-metabolic-syndrome-100640319",false,"NCT07577284","AI Chatbot-Enabled ePRO Symptom Monitoring and Self-Management for Early Cardiovascular-Kidney-Metabolic Syndrome","Inclusion Criteria:\n\n* Adults ≥40 years\n* Classified as having stage CKM syndrome (stage 1-2)\n* Receiving outpatient care\n* Able to communicate in Mandarin\u002FTaiwanese, and\n* Having access to a smartphone\u002Ftablet\n\nExclusion Criteria:\n\n* End-stage kidney disease requiring dialysis or are listed for kidney transplantation\n* Have terminal illness (\\\u003C6 months life expectancy)\n* Have significant cognitive impairment\n* Currently enrolled in another interventional study targeting cardiovascular-kidney-metabolic syndrome or multimorbidity","ALL","40 Years",{"count":59,"type":60},72,"ESTIMATED","INTERVENTIONAL",[63],"NA","This randomized clinical trial aims to evaluate whether an AI chatbot-enabled, nurse-led electronic patient-reported outcome (ePRO) intervention can improve symptom management and self-care in adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. The study will also assess the safety and feasibility of the intervention. Researchers will investigate whether the program reduces symptom burden, improves patient activation and health literacy, and lowers healthcare utilization such as emergency department visits and hospitalizations compared with usual ePRO monitoring alone. A total of 72 participants will be randomly assigned to either an intervention group, which receives weekly AI chatbot-supported symptom monitoring combined with nurse-led feedback and self-management support, or a control group receiving ePRO monitoring without feedback. Participants will complete PROMIS-29 assessments weekly and attend study evaluations at baseline, 3 months, and 6 months, while clinical outcomes and healthcare use are tracked through electronic medical records.",[66],"Cardiovascular Kidney Metabolic Syndrome",[68,69,70,71,72,73],"artificial intelligence","Chatbot","electronic patient-reported outcomes","patient activation","randomized controlled trial","cardiovascular kidney metabolic syndrome","NOT_YET_RECRUITING","2026-05-05",{"date":77,"type":78},"2026-05-11","ACTUAL",{"date":80,"type":60},"2026-05-30",{"date":82,"type":60},"2029-07-31",{"name":5,"class":6},1]